Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer - Wikidata - wikimedia - TriplyDB

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

http://www.wikidata.org/entity/Q24646000

about

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy Abiraterone in prostate cancer: a new angle to an old problem Abiraterone in the treatment of metastatic castration-resistant prostate cancer Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer Human steroid biosynthesis for the oncologist Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide Cytochrome P450 17A1 Interactions with the FMN Domain of Its Reductase as Characterized by NMR Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models A model of the membrane-bound cytochrome b5-cytochrome P450 complex from NMR and mutagenesis data.Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer.Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells CYP17A1 inhibitors in castration-resistant prostate cancer CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines New hormonal therapies for castration-resistant prostate cancer.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

P2860

Q21091046-596A8B24-0CF6-42E1-8A2C-7D899F331319 Q24603649-BEAFB053-49DE-4499-88CC-59F1E96BA16D Q24613957-3DD412A2-C594-4F60-87B5-6F2FEE27159E Q26739708-435ADD8F-AD15-42D7-8D40-EA72C02FBC16 Q26744431-1A0F95F1-C732-4BFE-A1CD-D4BD72CE9AC3 Q26750620-DB3EEB32-C7FA-47D2-B870-5A339FA5D508 Q26751237-4F3A6B2E-573A-49E0-81B1-84DEF73F5A38 Q26786543-685A735A-7B13-4953-8EE9-9C898E3B41A5 Q26828810-7A110549-840B-49EA-94B3-5D1A5546C933 Q26853635-BC354EEE-F947-48C2-B727-6EFA9B112AE6 Q26861575-15F7E9D8-85F1-4E5A-9A97-34EC2A1BC654 Q26865701-2B4F03D6-C0D7-487F-A5F2-54E43BC131C7 Q26999384-D7134B92-F681-440E-8232-EA0E37A6F86C Q27313709-D1AC1EE3-8BD6-413D-AEA0-81425A9A4374 Q27676555-8FE9E229-CE75-4002-9DB9-2C6E677ABC56 Q27678564-FA9A7B55-8EE9-40CD-98E1-D98734B2582C Q27853062-107C79CB-4A27-45A3-A470-041A3262E16A Q28076820-D0D91FE8-EBB7-4E14-9F05-24791B05B5D6 Q28271636-16DE1646-C3E9-4DD5-998E-50E5D1CD7400 Q28487784-D886C320-481D-45A2-909E-0327DC58DA86 Q30633058-A50888D0-DA1D-454E-B42E-2AD4D6B7BA95 Q31034242-CFF8145A-3780-4827-A280-D46AE3C6FEE9 Q33364957-FAE0E0B6-04C3-4ABA-B6DD-240518D00C6A Q33589156-C26A4996-6DF4-4F9D-946E-58CA263524FC Q33621403-DCAF5A05-720C-41DD-B377-5C5CD2DB2E16 Q33623428-50E6272D-9121-466D-908C-797628D93F4D Q33696276-63AF6D0F-84B7-4E4C-BA76-9AF5BD1C81F4 Q34115708-5362441E-9695-44B8-B3AF-AA02F4C45D8F Q34456638-362B7F99-688A-4388-B0E8-1FB298257A3D Q34604646-0BF3F211-14C0-4155-BB9C-680189B2BCB7 Q34956110-58D27E93-9CF9-47D5-A95D-7A27C3F0E553 Q35128716-0668BDF2-481A-4E28-B6B0-F8102E8FADBF Q35152021-A8D04037-098D-4084-A93D-5C904C3C03C7 Q35196715-057E19A5-DFC9-40A0-BC21-8439FE921808 Q35210730-B624BF50-E475-48BE-B8EB-22312F5CF52D Q35223874-C6012BD4-A3BE-492A-A78B-4B572756B9F2 Q35603660-B433D97E-AB78-4D61-AE49-08E358C69ED2 Q35713138-14B41A8F-95EE-4540-9F28-4C97B3FE0234 Q35816836-6F35988B-00CB-4E60-BEDF-B371FCA3BBF1 Q35881896-5ECEF9FC-F30F-436A-808C-50DFBEC699DB

P2860

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

http://www.wikidata.org/entity/Q24646000

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Hormonal impact of the 17alpha ...... patients with prostate cancer

@ast

Hormonal impact of the 17alpha ...... patients with prostate cancer

@en

Hormonal impact of the 17alpha ...... patients with prostate cancer

@nl

type

label

Hormonal impact of the 17alpha ...... patients with prostate cancer

@ast

Hormonal impact of the 17alpha ...... patients with prostate cancer

@en

Hormonal impact of the 17alpha ...... patients with prostate cancer

@nl

prefLabel

Hormonal impact of the 17alpha ...... patients with prostate cancer

@ast

Hormonal impact of the 17alpha ...... patients with prostate cancer

@en

Hormonal impact of the 17alpha ...... patients with prostate cancer

@nl

P1433

Q24646000-D2BC4216-15E2-40B4-B234-D211B9FBF8D9

P1476

Q24646000-195D02D2-2FB4-4E04-8EA6-78E8BE3F9232

P2093

Q24646000-05289FD6-5FF9-406B-AE50-D8815FD22202

Q24646000-3467A6B4-548F-47C1-98F9-140D23D52924

Q24646000-5716B578-0FD9-4F9F-A038-4B898FC4C4EB

Q24646000-59838D61-E57A-422B-A6FD-A4384CF6FA75

Q24646000-6352B0D4-7EBC-490B-9BE4-FF2A8F8032A5

Q24646000-642B750F-E310-4F04-821C-827C4E41B4B2

Q24646000-7FCF6772-147D-4E99-8425-5AEFCFEB0D08

Q24646000-B5595B8D-36D9-4BA4-9E23-035ED1357492

Q24646000-BDF1E336-6640-4DE2-A426-F01595FF4F66

Q24646000-D9C820FA-4FFC-41E9-8CC8-480427EFEBD9

P2860

Q24646000-15226ED7-90B2-4FE5-9164-035A3ADA0151

Q24646000-3A9D26FA-B68C-4636-A609-BBC202BFA668

Q24646000-3B63E085-D8DC-4269-87CF-BBF4A18C05EC

Q24646000-41E46482-6748-4647-8B0C-2224B3E363FD

Q24646000-5132112F-4278-4F4B-8913-EDC9C364366F

Q24646000-529839BE-E229-43F0-93F1-E6A28AB9124D

Q24646000-53057AA4-97CE-4FE9-AECE-51C611D1F844

Q24646000-547A229F-B2DE-469F-B933-5FBF7A7C32A4

Q24646000-5B9DEB14-19C5-4755-BE4B-0C709176043B

Q24646000-5BDF0C8C-A5AC-4CE7-B993-29DF5F903A85

P2888

Q24646000-E0CF7067-D1C5-40D6-AB91-E6ED0941E6E1

P304

Q24646000-637D03B2-02F5-4022-9662-BEB32835F7B0

P31

Q24646000-D5C1488B-D80A-4C07-A94E-760863A673F6

P3181

Q24646000-5560755A-400E-41F4-A293-5709E1190D17

P356

Q24646000-814DF0E7-1F9C-41A2-8792-DE133013D97A

P407

Q24646000-7739B192-DC4E-42BA-8D70-9F0375FF7C32

P433

Q24646000-C0AA19C3-A5E5-42F5-A9E6-1290373A8CA6

P478

Q24646000-8BE69670-2D07-4024-BED8-5C29B386088B

P50

Q24646000-FB48DECF-477B-4E58-95EE-2DFEF9CB404F

P577

Q24646000-577171FA-346D-4AB6-9640-B54C89537252

P5875

Q24646000-27DE0E83-A94B-427B-9F41-79B3CBE61AA5

P6179

Q24646000-E7E625BD-99A0-4272-B1CB-69EF5DFA5081

P698

Q24646000-3B400AE3-5B46-42FA-84D7-C2A56E8BAEC7

P921

Q24646000-D09F7CFF-2E10-4ADF-BB8C-D7964BAC08A4

Q24646000-E712BE73-329F-4900-990D-BF0BD6C2AF73

P932

Q24646000-9D8857EF-0C1B-4A0D-A893-6D0022109F1D

P3181

P356

P1433

British Journal of Cancer

P1476

Hormonal impact of the 17alpha ...... patients with prostate cancer

@en

P2093

A O'Donnell

http://www.w3.org/2001/XMLSchema#string

A Robbins

http://www.w3.org/2001/XMLSchema#string

B Nutley

http://www.w3.org/2001/XMLSchema#string

D Dearnaley

http://www.w3.org/2001/XMLSchema#string

G Halbert

http://www.w3.org/2001/XMLSchema#string

I Judson

http://www.w3.org/2001/XMLSchema#string

M Dowsett

http://www.w3.org/2001/XMLSchema#string

M Jarman

http://www.w3.org/2001/XMLSchema#string

M Mason

http://www.w3.org/2001/XMLSchema#string

S Harland

http://www.w3.org/2001/XMLSchema#string

P2860

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

A history of prostate cancer treatment

The current state of hormonal therapy for prostate cancer.

Secondary hormonal therapies in the treatment of prostate cancer.

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Oral chemotherapy: rationale and future directions.

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.

P2888

P304

2317-2325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1197242

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.BJC.6601879

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8554850

http://www.w3.org/2001/XMLSchema#string

P6179

1037763577

http://www.w3.org/2001/XMLSchema#string

P698

15150570

http://www.w3.org/2001/XMLSchema#string

P921

abiraterone acetate

P932

2409523

http://www.w3.org/2001/XMLSchema#string